Non-Hodgkin Lymphoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) HC (1) | CD20 + | Non-Hodgkin Lymphoma | Rituximab | |
| FDA (1) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Prednisolone, Rituximab, Vincristine | |
| FDA (1) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine | |
| FDA (1) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab | |
| FDA (2) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine |